Overexpression of CDH17 correlates with the presence of metastases and poor survival of colorectal cancer patients. Therapeutic Monoclonal Antibodies developed against the RGD-tripeptide motifs of Cadherins showed to be efficacious in in vitro and in vivo models for the treatment of metastatic colorectal, melanoma, renal, ovary or breast cancers.
Interleukin 13 alpha 2 receptor (IL13Rα2) expression in colorectal cancer is associated with late-stage tumors and lower survival of these patients. IL13Rα2 is also overexpressed in a wide variety of human tumor types such as glioblastoma, renal cell carcinoma, pancreatic, melanoma, head and neck, mesothelioma, and ovary. In glioblastoma, IL13Rα2 has been associated with a more aggressive form and a poorer patient prognosis.
Monoclonal antibodies anti-IL13Rα2 showed the ability to effectively compete and inhibit the binding of IL13 ligand to IL13Rα2 receptor.